Table 3.
Plasma Aβ peptides level of subjects.
| NC (N = 27) | LLOD (N = 29) | LLODwoMCI (N = 15) | LLODMCI (N = 14) | |
|---|---|---|---|---|
| Plasma Aβ1–42 | 39.58 ± 7.82 | 43.51 ± 11.19 | 43.22 ± 10.71 | 43.81 ± 12.08*a |
| Plasma Aβ1–40 | 176.03 ± 17.83 | 189.74 ± 35.68 | 179.54 ± 35.05 | 200.67 ± 34.21*a |
| Plasma AβN–42 | 27.95 ± 6.05 | 30.56 ± 9.29 | 30.86 ± 8.49 | 30.24 ± 10.40 |
| Plasma AβN–40 | 186.81 ± 22.54 | 195.19 ± 39.34 | 200.85 ± 45.49 | 189.12 ± 32.08 |
| Aβ1–40/Aβ1–42 | 4.61 ± 1.03 | 4.60 ± 1.32 | 4.35 ± 1.14 | 4.87 ± 1.47 |
| AβN–40/AβN–42 | 7.05 ± 2.13 | 7.13 ± 3.44 | 7.07 ± 2.82 | 7.21 ± 4.12 |
Data are presented as mean ± SD. Plasma Aβ peptide levels are shown as ng/L.
*
Significant difference compared to NC (p < 0.05).
a
LLODMCI subjects had significantly higher plasma Aβ1–42 and plasma Aβ1–40 peptides level compared to NC (p = 0.03 and p = 0.006, respectively) after controlling the effect of age, gender and educational level.
NC, Normal Controls; LLOD, Late-life Onset Depression; MCI, Mild Cognitive Impairment; LLODwoMCI, LLOD without MCI; Aβ, Beta-amyloid.